January/February 2011 Content
- Chief Medical Editor’s Page
- How to Create and Submit Videos to Eyetube.net
- Corneal Collagen Cross-linking
- Verbal Anesthesia
- Is There a Difference Between Re-esterified Triglyceride and Ethyl Ester Fish Oil?
- Progress in Understanding Prophylaxis for Endophthalmitis
- The Role of Angle Surgery
- Caring for the Glaucoma Patient With Uveitis
- Pediatric Uveitis Should Be Managed by a Team
- Anterior Uveitis: Etiology and Treatment
- Sustained-Release Steroidal Implants for the Treatment of Uveitis
- Sustained-Release Steroidal Implants for the Treatment of Uveitis
- Posterior Uveitis: an Overview
- Human Tears and Artificial Replacements
- Canalicular Lacerations
- INDUSTRY NEWS AND INNOVATIONS
- Guide to Building a Successful Clinical Research Program
Allergan Introduces Lastacaft for Ocular Itching
Allergan, Inc., launched Lastacaft (alcaftadine ophthalmic solution) 0.25% for the prevention of ocular itching due to allergic conjunctivitis, according to a news release.
Lastacaft, a new chemical entity with an affinity for H1, is approved by the FDA for dosing once daily in patients aged 2 years or older. In clinical studies, Lastacaft provided relief of ocular itching within 3 minutes in 97% of participants (n = 909), and one drop was shown to prevent ocular itching for 16 hours in 87% of patients.
Newest Videos
-
Genetic Testing for AMD
Added 48 days ago
-
Macula Risk
Added 9 months ago
-
Ocular Allergies as a Practice Builder
Added 48 days ago
-
Improving Compliance With Contact Lens Use
Added 48 days ago
